Verena I. Gaidzik

Targeting mutant VHL-gene results in therapy response in metastatic clear cell carcinoma of rete testis

Michael Karl Melzer, Angelika Mattigk, Verena I. Gaidzik, Nadine Therese Gaisa et autres

Epididymal and rete testis tumors are exceedingly rare. We report a 69-year-old male who presented with progressive swelling of the right testis/epididymis; histopathology confirmed clear cell carcinoma of the rete testis. Staging with FDG-PET-CT revealed bilateral pulmonary metastases. Subsequent gene panel sequencing …

de (code pays fourni par la source)

CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial

Maria‐Veronica Teleanu, Christoph E. Heilig, Sebastian Pirmann, Rainer Hamacher et autres

BACKGROUND: This study aims to evaluate antitumor response of palbociclib in patients with advanced chordoma, an ultra-rare cancer without approved systemic therapy. Previous data showed that palbociclib reduced cell viability and proliferation in CDKN2A-deficient chordoma cell lines. PATIENTS AND METHODS: We conducted …

de (code pays fourni par la source)

Correction: The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers

Siyer Roohani, Jolina Handtke, Kamal Hummedah, Markus Albertsmeier et autres

In this article, the author’s name Armin Tuchscherer was incorrectly written as Armin Tuscherer. The original article has been corrected.

de, at (code pays fourni par la source)

Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome– paving the path towards precision medicine: a case report

Carolin Seeling, Sonja Dahlum, Ralf Marienfeld, Vera Jan et autres

BACKGROUND: Li-Fraumeni syndrome (LFS) is an autosomal dominant tumor predisposition syndrome characterized by a high familial incidence of various malignancies. It results from pathogenic/likely pathogenic heterozygous constitutional variants of the TP53 gene. Due to impaired DNA damage repair, conventional cytotoxic therapies or …

de (code pays fourni par la source)

The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers

Siyer Roohani, Jolina Handtke, Kamal Hummedah, Markus Albertsmeier et autres

PURPOSE: The management of soft tissue sarcoma (STS) at reference centers with specialized multidisciplinary tumor boards (MTB) improves patient survival. The German Cancer Society (DKG) certifies sarcoma centers in German-speaking countries, promoting high standards of care. This study investigated the variability in …

de, at (code pays fourni par la source)

Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with NPM1‐mutated AML

Sibylle Cocciardi, Maral Saadati, Nina Weiß, Daniela Späth et autres

ABSTRACT This study aimed to evaluate the impact of the myelodysplasia‐related gene (MRG) as well as additional gene mutations on outcomes in intensively treated patients with NPM1‐mutated (NPM1mut) AML. Targeted DNA sequencing of 263 genes was performed in 568 NPM1mut AML patients …

de, us (code pays fourni par la source)

Rationale and Design of the Pamsarc (Pasireotide as Maintenance Treatment with Monthly Deep Intramuscular Injection in Sstr2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor) Multicenter Phase 2 Trial

Christoph E. Heilig, Christoph Heining, E. Gnutzmann, Sandra Roldan et autres

de (code pays fourni par la source)

Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial

Christoph E. Heilig, Christoph Heining, E. Gnutzmann, Sandra Roldan et autres

BACKGROUND: Desmoplastic small round cell tumor (DSRCT) and synovial sarcoma (SySa) are rare cancers primarily affecting adolescents and young adults. Prognosis is generally poor, particularly upon metastasis, due to limited efficacy of chemotherapies and the lack of molecular mechanism-based approaches. Recently, overexpression …

de (code pays fourni par la source)

Standardized Response Assessment in Patients with Advanced Cholangiocarcinoma Treated with Personalized Therapy

Stephan Ursprung, Wolfgang Thaiss, Janina Beha, Yvonne Möller et autres

Background/Objectives: Current guidelines recommend Cisplatin/Gemcitabine/Durvalumab as first-line treatment for inoperable or recurrent cholangiocarcinoma (CCA). Molecular tumor boards (MTB) have the expertise to support organ-specific tumor boards with evidence-based treatment recommendations for subsequent lines of treatment, based on genomic tumor data and scientific …

de (code pays fourni par la source)

Leiomyosarkom: Fortschritte in der Erstlinientherapie dank Kombinationstherapien

Verena I. Gaidzik

Die randomisierte LMS04 Studie der French Sarcoma Group zeigte, dass die Kombinationstherapie aus Doxorubicin und Trabectedin, gefolgt von einer Trabectedin-Erhaltungstherapie, das Gesamtüberleben (33 versus 24 Monate) und das progressionsfreie Überleben (12 versus 6 Monate) im Vergleich zur alleinigen Doxorubicin-Therapie bei Patient*innen mit …

de (code pays fourni par la source)

Osteolytische Raumforderung des Mittelgesichts

Johannes Schulze, Andreas Sakkas, Sebastian Pietzka, Frank Wilde et autres

de (code pays fourni par la source)

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin

Frank G. Rücker, Lars Bullinger, Sibylle Cocciardi, Sabrina Skambraks et autres

ABSTRACT: Measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITDpos) has been hampered by the broad heterogeneity of ITD mutations. Using our recently developed FLT3-ITD paired-end next-generation sequencing (NGS)-based MRD assay (limit of detection …

de (code pays fourni par la source)